AZD1152 in Patients With Advanced Solid Malignancies

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Tumors

Treatments: Drug: AZD1152 part B; Drug: AZD1152 part A

Study type: Interventional

Funder types: Industry

Identifiers

NCT00338182

D1531C00002

Details and patient eligibility

About

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.

Enrollment: 43 patients

Sex: All

Ages: 18 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological or cytological confirmation of a solid, malignant tumour
• At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Exclusion criteria

• Participation in an investigational drug study within the 21 days prior to therapy or those who have not recovered from the effects of an investigational study drug
• Recent major surgery within 4 weeks prior to entry into the study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

43 participants in 1 patient group

AZD1152

Experimental group

Description:

AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment)

Treatment:

Drug: AZD1152 part A

Drug: AZD1152 part B